Reader, GB
Alec Reader, Southampton GB
Patent application number | Description | Published |
---|---|---|
20110204483 | Electroluminescent device for the production of ultra-violet light - The invention provides a method of producing an opto-electronic device wherein a layer of lattice matched material is grown on a substrate, the lattice matched material being a cubic zincblend material and the substrate being a cubic diamond or zincblend material, to form a coated substrate. | 08-25-2011 |
John C. Reader, Linton GB
Patent application number | Description | Published |
---|---|---|
20110071134 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRIMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES - A heterocyclic inhibitor having the formula I, with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role: | 03-24-2011 |
John Charles Reader, Cambridgeshire GB
Patent application number | Description | Published |
---|---|---|
20100331328 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation: | 12-30-2010 |
John Charles Reader, Linton GB
Patent application number | Description | Published |
---|---|---|
20120040967 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation. | 02-16-2012 |
20130102592 | OXAZOLE TYROSINE KINASE INHIBITORS - The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar | 04-25-2013 |
20130231340 | PHARMACEUTICAL COMPOUNDS - The invention provides a method of inhibiting a TYK2 kinase, which method comprises bringing into contact with the TYK2 kinase an effective TYK2 kinase-inhibiting amount of a compound having the formula (0): | 09-05-2013 |
20140275041 | OXAZOLE TYROSINE KINASE INHIBITORS - The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar | 09-18-2014 |
20150057282 | OXAZOLE TYROSINE KINASE INHIBITORS - The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar | 02-26-2015 |
John Charles Reader, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20100210639 | 9H-PYRIMIDO[4,5-B]INDOLES, 9H-PYRIDO[4',3':4,5]PYRROLO[2,3-D]PYRIDINES, AND 9H 1,3,6,9 TETRAAZA-FLUORENES AS CHK1 KINASE FUNCTION INHIBITORS - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain tricyclic compounds (referred to herein as TC compounds), and especially certain 9H-pyrimido[4,5-b]indole, 9H-pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyridine, and 9H-1,3,6,9-tetraaza-fluorene compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation. | 08-19-2010 |
20100298301 | OXAZOLE TYROSINE KINASE INHIBITORS - The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar | 11-25-2010 |
20140315925 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyridyl-amino-pyrazine carbonitrile compounds that, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation. | 10-23-2014 |
20150018367 | AURORA AND FLT3 KINASES MODULATORS - The invention provides a compound having the formula (1): | 01-15-2015 |
John Edward Hubbard Reader, Suffolk GB
Patent application number | Description | Published |
---|---|---|
20100065044 | SOLAR THERMAL PANEL AND METHOD OF MANUFACTURE - A solar thermal panel is disclosed. The solar thermal panel includes a body, the body comprising a plurality of rubber particles bound by a binding agent and defining one or more channels within the body, the or each channel including a fluid inlet and a fluid outlet connectable to a fluid circulation circuit. | 03-18-2010 |
20100192602 | ABSORPTION COOLING SYSTEM AND COOLING METHOD - An adsorption cooling system and cooling method as disclosed. An energy storage system is arranged to capture and store energy generated by the adsorption cooling system that is determined to be surplus to the energy needed to meet the current demands for cooling by the adsorption cooling system. The energy storage system is arranged to store said energy for subsequent use. | 08-05-2010 |
Michael Reader, Bishop'S Stortford GB
Patent application number | Description | Published |
---|---|---|
20130072457 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS - The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. | 03-21-2013 |
Valerie Reader, Linton GB
Patent application number | Description | Published |
---|---|---|
20090238808 | Process for the identification of novel enzyme interacting compounds - The present invention relates to methods for the characterization of enzymes or of enzyme-compound complexes, wherein the enzyme is obtained from a protein preparation with the help of at least one broad spectrum ligand immobilized on a solid support and wherein the enzyme is characterized by mass spectrometry. These methods are useful for the screening of non-immobilized compound libraries, selectivity profiling of lead compounds and mechanism of action studies in living cells. | 09-24-2009 |
20140179664 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors - The present invention relates to compounds of formula (I) | 06-26-2014 |
Valerie Reader, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20090118289 | (Biphenyl) Carboxylic Acids and Derivatives Thereof - The present invention relates to compounds having the general formula (I) with the definitions of A, X, R | 05-07-2009 |
20090220992 | METHODS FOR THE IDENTIFICATION OF LRRK2 INTERACTING MOLECULES AND FOR THE PURIFICATION OF LRRK2 - The invention provides in a first aspect a method for the identification of an LRRK2 interacting compound, comprising the steps of providing a protein preparation containing LRRK2, contacting the protein preparation with indol ligand 91 immobilized on a solid support under conditions allowing the formation of an indol ligand 91-LRRK2 complex, incubating the indol ligand 91-LRRK2 complex with a given compound, and determining whether the compound is able to separate LRRK2 from the immobilized indol ligand 91. Furthermore, the invention relates to a method for the identification of an LRRK2 interacting compound, comprising the steps of providing a protein preparation containing LRRK2, contacting the protein preparation with indol ligand 91 immobilized on a solid support and with a given compound under conditions allowing the formation of an indol ligand 91-LRRK2 complex, and detecting the indol ligand 91-LRRK2 complex. Additionally, the invention provides a method for the identification of an LRRK2 interacting compound, comprising the steps of providing two aliquots of a protein preparation containing LRRK2, contacting one aliquot with indol ligand 91 immobilized on a solid support under conditions allowing the formation of an indol ligand 91-LRRK2 complex, contacting the other aliquot with indol ligand 91 immobilized on a solid support and with a given compound under conditions allowing the formation of an indol ligand 91-LRRK2 complex, and determining the amount of indol ligand 91-LRRK2 complex. Furthermore, the invention relates to a method for the purification of LRRK2, comprising the steps of providing a protein preparation containing LRRK2, contacting the protein preparation with indol ligand 91 immobilized on a solid support under conditions allowing the formation of an indol ligand 91-LRRK2 complex, and separating LRRK2 from the immobilized indol ligand 91. | 09-03-2009 |
20110070595 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS - The present invention relates to immobilization compounds and methods useful for the identification of PARP interacting compounds or for the purification or identification of PARP proteins. | 03-24-2011 |